The synaptic function of α-synuclein

Journal of Parkinson's Disease

Volumn 5, Issue 4, 2015, Pages 699-713

  Burré, Jacqueline ^a  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

membranes; neurotransmitter release; SNARE; synapse; synaptic vesicles; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE;

BIOGENESIS; CELLULAR DISTRIBUTION; CYTOSOL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HUMAN; LIPID PACKING; LIPID TRANSPORT; MOLECULAR BIOLOGY; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; SYNAPSE; METABOLISM; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; HUMANS; PARKINSON DISEASE; SYNAPSES;

EID: 84952645933     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150642     Document Type: Review

References (259)

1. Maroteaux L, Campanelli JT, Scheller RH, 1988 Synuclein: A neuron-secific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 2804 2815
2. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T, 1993 Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90 11282 11286
3. Nakajo S, Omata K, Aiuchi T, Shibayama T, Okahashi I, Ochiai H, Nakai Y, Nakaya K, Nakamura Y, 1990 Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem 55 2031 2038
4. Jakes R, Spillantini MG, Goedert M, 1994 Identification of two distinct synucleins from human brain. FEBS Lett 345 27 32
5. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, Polymeropoulos MH, 1998 Identification, localization and characterization of the human gamma-synuclein gene. Hum Genet 103 106 112
6. Buchman VL, Hunter HJ, Pinon LG, Thompson J, Privalova EM, Ninkina NN, Davies AM, 1998 Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci 18 9335 9341
7. Galvin JE, Uryu K, Lee VM, Trojanowski JQ, 1999 Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A 96 13450 13455
8. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, 1998 alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95 6469 6473
9. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M, 1998 Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251 205 208
10. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, Lee VM, 1998 Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44 415 422
11. Gai WP, Power JH, Blumbergs PC, Blessing WW, 1998 Multiple-system atrophy: A new alpha-synuclein disease? Lancet 352 547 548
12. Lewis KA, Su Y, Jou O, Ritchie C, Foong C, Hynan LS, White CL 3rd, Thomas PJ, Hatanpaa KJ, 2010 Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. Am J Pathol 177 3037 3050
13. Hamilton RL, 2000 Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10 378 384
14. Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E, Kuzuhara S, Ihara Y, Kanazawa I, Murayama S, 2000 Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 177 48 59
15. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ, 2000 Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157 361 368
16. Arawaka S, Saito Y, Murayama S, Mori H, 1998 Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51 887 889
17. Mori F, Hayashi S, Yamagishi S, Yoshimoto M, Yagihashi S, Takahashi H, Wakabayashi K, 2002 Pick's disease: Alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus. Acta Neuropathol 104 455 461
18. Nishioka K, Wider C, Vilarino-Guell C, Soto-Ortolaza AI, Lincoln SJ, Kachergus JM, Jasinska-Myga B, Ross OA, Rajput A, Robinson CA, Ferman TJ, Wszolek ZK, Dickson DW, Farrer MJ, 2010 Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol 67 970 975
19. Wirths O, Weickert S, Majtenyi K, Havas L, Kahle PJ, Okochi M, Haass C, Multhaup G, Beyreuther K, Bayer TA, 2000 Lewy body variant of Alzheimer's disease: Alpha-synuclein in dystrophic neurites of A beta plaques. Neuroreport 11 3737 3741
20. Doherty MJ, Bird TD, Leverenz JB, 2004 Alpha-synuclein in motor neuron disease: An immunohistologic study. Acta Neuropathol 107 169 175
21. Takei Y, Oguchi K, Koshihara H, Hineno A, Nakamura A, Ohara S, 2013 alpha-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. Hum Pathol 44 1171 1176
22. Yamazaki M, Arai Y, Baba M, Iwatsubo T, Mori O, Katayama Y, Oyanagi K, 2000 Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 59 585 591
23. Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VM, Trojanowski JQ, 2002 Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol 160 1725 1731
24. Arai K, Kato N, Kashiwado K, Hattori T, 2000 Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 296 171 173
25. Wilhelmsen KC, Forman MS, Rosen HJ, Alving LI, Goldman J, Feiger J, Lee JV, Segall SK, Kramer JH, Lomen-Hoerth C, Rankin KP, Johnson J, Feiler HS, Weiner MW, Lee VM, Trojanowski JQ, Miller BL, 2004 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. Arch Neurol 61 398 406
26. Yancopoulou D, Xuereb JH, Crowther RA, Hodges JR, Spillantini MG, 2005 Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia. J Neuropathol Exp Neurol 64 245 253
27. Judkins AR, Forman MS, Uryu K, Hinkle DA, Asbury AK, Lee VM, Trojanowski JQ, 2002 Co-occurrence of Parkinson's disease with progressive supranuclear palsy. Acta Neuropathol 103 526 530
28. Mori H, Oda M, Komori T, Arai N, Takanashi M, Mizutani T, Hirai S, Mizuno Y, 2002 Lewy bodies in progressive supranuclear palsy. Acta Neuropathol 104 273 278
29. Yamashita S, Sakashita N, Yamashita T, Tawara N, Tasaki M, Kawakami K, Komohara Y, Fujiwara Y, Kamikawa M, Nakagawa T, Hirano T, Maeda Y, Hasegawa M, Takeya M, Ando Y, 2014 Concomitant accumulation of alpha-synuclein and TDP-43 in a patient with corticobasal degeneration. J Neurol 261 2209 2217
30. Smith BR, Santos MB, Marshall MS, Cantuti-Castelvetri L, Lopez-Rosas A, Li G, van Breemen R, Claycomb KI, Gallea JI, Celej MS, Crocker SJ, Givogri MI, Bongarzone ER, 2014 Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease. J Pathol 232 509 521
31. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T, 2009 Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41 1308 1312
32. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T, 1995 The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 467 475
33. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K, 2002 Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. Brain Res 941 118 126
34. Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Ueda K, Chan P, 2007 Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 145 539 555
35. Totterdell S, Hanger D, Meredith GE, 2004 The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain. Brain Res 1004 61 72
36. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, Ohtaka-Maruyama C, Okado H, Hashimoto M, 2007 Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun 358 104 110
37. Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A, 2000 Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 59 592 598
38. Ltic S, Perovic M, Mladenovic A, Raicevic N, Ruzdijic S, Rakic L, Kanazir S, 2004 Alpha-synuclein is expressed in different tissues during human fetal development. J Mol Neurosci 22 199 204
39. Tamo W, Imaizumi T, Tanji K, Yoshida H, Mori F, Yoshimoto M, Takahashi H, Fukuda I, Wakabayashi K, Satoh K, 2002 Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci Lett 326 5 8
40. Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH, Kim J, 2000 Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Mol Cells 10 65 70
41. Kim S, Jeon BS, Heo C, Im PS, Ahn TB, Seo JH, Kim HS, Park CH, Choi SH, Cho SH, Lee WJ, Suh YH, 2004 Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J 18 1615 1617
42. Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, Kittel A, Saitoh T, Miller A, Masliah E, 1997 NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237 611 616
43. Li QX, Campbell BC, McLean CA, Thyagarajan D, Gai WP, Kapsa RM, Beyreuther K, Masters CL, Culvenor JG, 2002 Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. J Alzheimers Dis 4 309 315
44. Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH, 1998 Genomic organization and expression of the human beta-synuclein gene (SNCB). Genomics 54 173 175
45. Nakajo S, Tsukada K, Omata K, Nakamura Y, Nakaya K, 1993 A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur J Biochem 217 1057 1063
46. Ninkina N, Peters OM, Connor-Robson N, Lytkina O, Sharfeddin E, Buchman VL, 2012 Contrasting effects of alpha-synuclein and gamma-synuclein on the phenotype of cysteine string protein alpha (CSPalpha) null mutant mice suggest distinct function of these proteins in neuronal synapses. J Biol Chem 287 44471 44477
47. Ninkina NN, Alimova-Kost MV, Paterson JW, Delaney L, Cohen BB, Imreh S, Gnuchev NV, Davies AM, Buchman VL, 1998 Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet 7 1417 1424
48. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Takahashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, Trojanowski JQ, Ishikawa A, Idezuka J, Murata M, Toda T, Bird TD, Leverenz JB, Tsuji S, La Spada AR, 2004 Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63 805 811
49. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, Rockenstein E, Laspada AR, Masliah E, Inoue S, Hashimoto M, 2010 A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Nat Commun 1 110
50. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL, 2009 Gamma-synucleinopathy: Neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18 1779 1794
51. Peters OM, Millership S, Shelkovnikova TA, Soto I, Keeling L, Hann A, Marsh-Armstrong N, Buchman VL, Ninkina N, 2012 Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis 48 124 131
52. Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E, 2001 Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 914 48 56
53. Myerowitz R, Mizukami H, Richardson KL, Finn LS, Tifft CJ, Proia RL, 2004 Global gene expression in a type 2 Gaucher disease brain. Mol Genet Metab 83 288 296
54. Peters OM, Shelkovnikova T, Highley JR, Cooper-Knock J, Hortobagyi T, Troakes C, Ninkina N, Buchman VL, 2015 Gamma-synuclein pathology in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2 29 37
55. Kholodilov NG, Neystat M, Oo TF, Lo SE, Larsen KE, Sulzer D, Burke RE, 1999 Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem 73 2586 2599
56. Petersen K, Olesen OF, Mikkelsen JD, 1999 Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience 91 651 659
57. Chu Y, Kordower JH, 2007 Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 25 134 149
58. Withers GS, George JM, Banker GA, Clayton DF, 1997 Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 99 87 94
59. Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E, 1998 Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 71 338 344
60. Bayer TA, Jakala P, Hartmann T, Egensperger R, Buslei R, Falkai P, Beyreuther K, 1999 Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10 2799 2803
61. Galvin JE, Schuck TM, Lee VM, Trojanowski JQ, 2001 Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. Exp Neurol 168 347 355
62. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, Okochi M, Leimer U, van Der Putten H, Probst A, Kremmer E, Kretzschmar HA, Haass C, 2000 Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 20 6365 6373
63. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC, 2010 Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329 1663 1667
64. Zaltieri M, Grigoletto J, Longhena F, Navarria L, Favero G, Castrezzati S, Colivicchi MA, Corte LD, Rezzani R, Pizzi M, Benfenati F, Spillantini MG, Missale C, Spano P, Bellucci A, 2015 Alpha-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J Cell Sci 128 2231 2243
65. Chen RH, Wislet-Gendebien S, Samuel F, Visanji NP, Zhang G, Marsilio D, Langman T, Fraser PE, Tandon A, 2013 alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol Chem 288 7438 7449
66. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM, 2000 Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20 3214 3220
67. George JM, 2002 The synucleins. Genome Biol 3. REVIEWS3002
68. Bussell R Jr, Eliezer D, 2003 A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol 329 763 778
69. Davidson WS, Jonas A, Clayton DF, George JM, 1998 Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273 9443 9449
70. Eliezer D, Kutluay E, Bussell R Jr, Browne G, 2001 Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307 1061 1073
71. Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC, 2003 A broken alpha -helix in folded alpha -Synuclein. J Biol Chem 278 15313 15318
72. Bussell R Jr, Ramlall TF, Eliezer D, 2005 Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci 14 862 872
73. Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM, Veglia G, 2014 Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nat Commun 5 3827
74. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ, 2013 Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 28 811 813
75. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O, 1998 Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 106 108
76. Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, Pieri L, Madiona K, Durr A, Melki R, Verny C, Brice A, 2013 G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 73 459 471
77. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL, 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 2045 2047
78. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH, 2013 A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80 1062 1064
79. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG, 2004 The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 164 173
80. Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Poyhonen M, Paetau A, 2014 Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging 35 2180 e2181 e2185
81. Ulmer TS, Bax A, Cole NB, Nussbaum RL, 2005 Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem 280 9595 9603
82. Oueslati A, Fournier M, Lashuel HA, 2010 Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Imlications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 183 115 145
83. Fernandez CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, Jovin TM, 2004 NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J 23 2039 2046
84. Brown DR, 2007 Interactions between metals and alpha-synuclein-function or artefact? FEBS J 274 3766 3774
85. Paik SR, Shin HJ, Lee JH, Chang CS, Kim J, 1999 Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 340 Pt 3 821 828
86. Nielsen MS, Vorum H, Lindersson E, Jensen PH, 2001 Ca2binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem 276 22680 22684
87. Bodner CR, Dobson CM, Bax A, 2009 Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J Mol Biol 390 775 790
88. Sevcsik E, Trexler AJ, Dunn JM, Rhoades E, 2011 Allostery in a disordered protein: Oxidative modifications to alha-synuclein act distally to regulate membrane binding. J Am Chem Soc 133 7152 7158
89. Hoyer W, Cherny D, Subramaniam V, Jovin TM, 2004 Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43 16233 16242
90. Park SM, Jung HY, Kim TD, Park JH, Yang CH, Kim J, 2002 Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J Biol Chem 277 28512 28520
91. Crowther RA, Jakes R, Spillantini MG, Goedert M, 1998 Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436 309 312
92. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr, 1996 NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 13709 13715
93. Kim J, 1997 Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells 7 78 83
94. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA, 2012 alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287 15345 15364
95. Burré J, Vivona S, Diao J, Sharma M, Brunger AT, Sudhof TC, 2013 Properties of native brain alpha-synuclein. Nature 498 E4 E6. discussion E6-7
96. Bartels T, Choi JG, Selkoe DJ, 2011 alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 107 110
97. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK, Ju S, Cookson MR, Asturias FJ, Agar JN, Webb BN, Kang C, Ringe D, Petsko GA, Pochapsky TC, Hoang QQ, 2011 A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 108 17797 17802
98. Binolfi A, Theillet FX, Selenko P, 2012 Bacterial in-cell NMR of human alpha-synuclein: A disordered monomer by nature? Biochem Soc Trans 40 950 954
99. Smaldone G, Diana D, Pollegioni L, Di Gaetano S, Fattorusso R, Pedone E, 2015 Insight into conformational modification of alpha-synuclein in the presence of neuronal whole cells and of their isolated membranes. FEBS Lett 589 798 804
100. Burré J, Sharma M, Sudhof TC, 2014 alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A 111 E4274 E4283
101. Luth ES, Bartels T, Dettmer U, Kim NC, Selkoe DJ, 2015 Purification of alpha-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry 54 279 292
102. Middleton ER, Rhoades E, 2010 Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys J 99 2279 2288
103. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE, 2000 alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275 34328 34334
104. Perrin RJ, Woods WS, Clayton DF, George JM, 2000 Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J Biol Chem 275 34393 34398
105. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL, 2005 A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280 31664 31672
106. Bisaglia M, Schievano E, Caporale A, Peggion E, Mammi S, 2006 The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: A cooperative role. Biopolymers 84 310 316
107. Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D, 2010 The lipid-binding domain of wild type and mutant alpha-synuclein: Comactness and interconversion between the broken and extended helix forms. J Biol Chem 285 28261 28274
108. Trexler AJ, Rhoades E, 2009 Alpha-synuclein binds large unilamellar vesicles as an extended helix. Biochemistry 48 2304 2306
109. Jao CC, Der-Sarkissian A, Chen J, Langen R, 2004 Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A 101 8331 8336
110. Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D, 2008 Membrane-bound alpha-synuclein forms an extended helix: Long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J Am Chem Soc 130 12856 12857
111. Jao CC, Hegde BG, Chen J, Haworth IS, Langen R, 2008 Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc Natl Acad Sci U S A 105 19666 19671
112. Borbat P, Ramlall TF, Freed JH, Eliezer D, 2006 Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J Am Chem Soc 128 10004 10005
113. Drescher M, Veldhuis G, van Rooijen BD, Milikisyants S, Subramaniam V, Huber M, 2008 Antiparallel arrangement of the helices of vesicle-bound alpha-synuclein. J Am Chem Soc 130 7796 7797
114. Nuscher B, Kamp F, Mehnert T, Odoy S, Haass C, Kahle PJ, Beyer K, 2004 Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. J Biol Chem 279 21966 21975
115. Kang L, Moriarty GM, Woods LA, Ashcroft AE, Radford SE, Baum J, 2012 N-terminal acetylation of alpha-synuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer. Protein Sci 21 911 917
116. Maltsev AS, Ying J, Bax A, 2012 Impact of N-terminal acetylation of alpha-synuclein on its random coil and lipid binding properties. Biochemistry 51 5004 5013
117. Dikiy I, Eliezer D, 2014 N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound alpha-synuclein and increases its affinity for physiological membranes. J Biol Chem 289 3652 3665
118. Bartels T, Kim NC, Luth ES, Selkoe DJ, 2014 N-alpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One 9 e103727
119. Trexler AJ, Rhoades E, 2012 N-Terminal acetylation is critical for forming alpha-helical oligomer of alpha-synuclein. Protein Sci 21 601 605
120. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T, 2002 alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4 160 164
121. McFarland MA, Ellis CE, Markey SP, Nussbaum RL, 2008 Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics 7 2123 2137
122. Chen L, Feany MB, 2005 Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8 657 663
123. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA, 2010 Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30 3184 3198
124. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB, 2009 Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119 3257 3265
125. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA, 2008 Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 283 16895 16905
126. Nonaka T, Iwatsubo T, Hasegawa M, 2005 Ubiquitination of alpha-synuclein. Biochemistry 44 361 368
127. Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S, 2008 Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 283 3316 3328
128. Dorval V, Fraser PE, 2006 Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J Biol Chem 281 9919 9924
129. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, Bossis G, Urlaub H, Zweckstetter M, Kugler S, Melchior F, Bahr M, Weishaupt JH, 2011 Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194 49 60
130. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P, 2000 Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20 253 257
131. Shaikh S, Nicholson LF, 2008 Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86 2071 2082
132. Padmaraju V, Bhaskar JJ, Prasada Rao UJ, Salimath PV, Rao KS, 2011 Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein. J Alzheimers Dis 24 Suppl 2 211 221
133. Alfaro JF, Gong CX, Monroe ME, Aldrich JT, Clauss TR, Purvine SO, Wang Z, Camp DG 2nd, Shabanowitz J, Stanley P, Hart GW, Hunt DF, Yang F, Smith RD, 2012 Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc Natl Acad Sci U S A 109 7280 7285
134. Marotta NP, Cherwien CA, Abeywardana T, Pratt MR, 2012 O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation. Chembiochem 13 2665 2670
135. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM, 2000 Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 985 989
136. Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H, 2004 Functional consequences of alpha-synuclein tyrosine nitration: Diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279 47746 47753
137. Yamin G, Uversky VN, Fink AL, 2003 Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542 147 152
138. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, Lee MK, 2005 Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102 2162 2167
139. Murray IV, Giasson BI, Quinn SM, Koppaka V, Axelsen PH, Ischiropoulos H, Trojanowski JQ, Lee VM, 2003 Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 8530 8540
140. Lokappa SB, Suk JE, Balasubramanian A, Samanta S, Situ AJ, Ulmer TS, 2014 Sequence and membrane determinants of the random coil-helix transition of alpha-synuclein. J Mol Biol 426 2130 2144
141. Zhu M, Fink AL, 2003 Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem 278 16873 16877
142. Burré J, Sharma M, Sudhof TC, 2015 Definition of a molecular pathway mediating alpha-synuclein neurotoxicity. J Neurosci 35 5221 5232
143. Jo E, Darabie AA, Han K, Tandon A, Fraser PE, McLaurin J, 2004 alpha-Synuclein-synaptosomal membrane interactions: Implications for fibrillogenesis. Eur J Biochem 271 3180 3189
144. Narayanan V, Scarlata S, 2001 Membrane binding and self-association of alpha-synucleins. Biochemistry 40 9927 9934
145. Lee HJ, Choi C, Lee SJ, 2002 Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem 277 671 678
146. Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S, 2014 alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 24 2319 2326
147. Conway KA, Harper JD, Lansbury PT, 1998 Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4 1318 1320
148. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A, 1998 Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 440 71 75
149. Conway KA, Harper JD, Lansbury PT Jr, 2000 Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 2552 2563
150. Uversky VN, 2007 Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103 17 37
151. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr, 2002 Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322 1089 1102
152. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K, 2003 alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 841
153. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A, 2004 Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 1169 1171
154. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L, 2000 Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287 1265 1269
155. Kahle PJ, Neumann M, Ozmen L, Haass C, 2000 Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci 920 33 41
156. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E, 2002 Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68 568 578
157. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A, 2000 Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 239 252
158. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL, 2002 Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22 8797 8807
159. Burré J, Sharma M, Sudhof TC, 2012 Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci 32 15227 15242
160. Gorbatyuk OS, Li S, Nguyen FN, Manfredsson FP, Kondrikova G, Sullivan LF, Meyers C, Chen W, Mandel RJ, Muzyczka N, 2010 alpha-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration. Mol Ther 18 1758 1768
161. Jenco JM, Rawlingson A, Daniels B, Morris AJ, 1998 Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37 4901 4909
162. Payton JE, Perrin RJ, Woods WS, George JM, 2004 Structural determinants of PLD2 inhibition by alpha-synuclein. J Mol Biol 337 1001 1009
163. Rappley I, Gitler AD, Selvy PE, LaVoie MJ, Levy BD, Brown HA, Lindquist S, Selkoe DJ, 2009 Evidence that alpha-synuclein does not inhibit phospholipase D. Biochemistry 48 1077 1083
164. Guo JT, Chen AQ, Kong Q, Zhu H, Ma CM, Qin C, 2008 Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol 28 35 47
165. Wersinger C, Rusnak M, Sidhu A, 2006 Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur J Neurosci 24 55 64
166. Butler B, Goodwin S, Saha K, Becker J, Sambo D, Davari P, Khoshbouei H, 2015 Dopamine Transporter Activity Is Modulated by alpha-synuclein. J Biol Chem
167. Swant J, Goodwin JS, North A, Ali AA, Gamble-George J, Chirwa S, Khoshbouei H, 2011 alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol Chem 286 43933 43943
168. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ, 2002 A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 3090 3099
169. Baptista MJ, O'Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, Farrer MJ, Cookson MR, 2003 Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85 957 968
170. Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, Ueda K, Chan P, 2004 Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367 34 39
171. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK, 2008 Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283 9089 9100
172. Li WW, Yang R, Guo JC, Ren HM, Zha XL, Cheng JS, Cai DF, 2007 Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 18 1543 1546
173. Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, Edwards RH, 2008 Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci 28 12305 12317
174. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC, 2010 Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell 21 1850 1863
175. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, Cao S, Caldwell KA, Caldwell GA, Marsischky G, Kolodner RD, Labaer J, Rochet JC, Bonini NM, Lindquist S, 2006 Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 324 328
176. Kontopoulos E, Parvin JD, Feany MB, 2006 Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15 3012 3023
177. Golovko MY, Faergeman NJ, Cole NB, Castagnet PI, Nussbaum RL, Murphy EJ, 2005 Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 44 8251 8259
178. Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barcelo-Coblijn GC, Nussbaum RL, 2005 Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 25 10190 10201
179. Barcelo-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ, 2007 Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 101 132 141
180. Rappley I, Myers DS, Milne SB, Ivanova PT, Lavoie MJ, Brown HA, Selkoe DJ, 2009 Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J Neurochem 111 15 25
181. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ, 2001 alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 98 9110 9115
182. Lucke C, Gantz DL, Klimtchuk E, Hamilton JA, 2006 Interactions between fatty acids and alpha-synuclein. J Lipid Res 47 1714 1724
183. Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, Langen R, 2010 Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J Biol Chem 285 32486 32493
184. Westphal CH, Chandra SS, 2013 Monomeric synucleins generate membrane curvature. J Biol Chem 288 1829 1840
185. Jiang Z, de Messieres M, Lee JC, 2013 Membrane remodeling by alpha-synuclein and effects on amyloid formation. J Am Chem Soc 135 15970 15973
186. Mizuno N, Varkey J, Kegulian NC, Hegde BG, Cheng N, Langen R, Steven AC, 2012 Remodeling of lipid vesicles into cylindrical micelles by alpha-synuclein in an extended alpha-helical conformation. J Biol Chem 287 29301 29311
187. Shi Z, Sachs JN, Rhoades E, Baumgart T, 2015 Biophysics of alpha-synuclein induced membrane remodelling. Phys Chem Chem Phys 17 15561 15568
188. Braun AR, Lacy MM, Ducas VC, Rhoades E, Sachs JN, 2014 alpha-Synuclein-induced membrane remodeling is driven by binding affinity, partition depth, and interleaflet order asymmetry. J Am Chem Soc 136 9962 9972
189. Madine J, Doig AJ, Middleton DA, 2006 A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45 5783 5792
190. Adamczyk A, Kacprzak M, Kazmierczak A, 2007 Alpha-synuclein decreases arachidonic acid incorporation into rat striatal synaptoneurosomes. Folia Neuropathol 45 230 235
191. Kamp F, Beyer K, 2006 Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J Biol Chem 281 9251 9259
192. Ouberai MM, Wang J, Swann MJ, Galvagnion C, Guilliams T, Dobson CM, Welland ME, 2013 alpha-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem 288 20883 20895
193. Braun AR, Sevcsik E, Chin P, Rhoades E, Tristram-Nagle S, Sachs JN, 2012 alpha-Synuclein induces both positive mean curvature and negative Gaussian curvature in membranes. J Am Chem Soc 134 2613 2620
194. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K, 2007 Parkinson's disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113 421 429
195. Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, Hasegawa T, Sugeno N, Konno M, Suzuki K, Takahashi S, Fukuda H, Aoki M, Itoyama Y, Mori E, Takeda A, 2012 Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: A 3 year longitudinal study. Brain 135 161 169
196. Sulzer D, Surmeier DJ, 2013 Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 28 715 724
197. Fahn S, Sulzer D, 2004 Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1 139 154
198. Riederer P, Wuketich S, 1976 Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38 277 301
199. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, 1973 Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20 415 455
200. Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A, 2013 Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One 8 e60378
201. Wersinger C, Sidhu A, 2003 Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett 340 189 192
202. Wersinger C, Prou D, Vernier P, Sidhu A, 2003 Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 17 2151 2153
203. Lee FJ, Liu F, Pristupa ZB, Niznik HB, 2001 Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15 916 926
204. Li YH, Gao N, Ye YW, Li X, Yu S, Yang H, Ueda K, Chan P, 2011 Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase. Acta Neurol Belg 111 130 135
205. Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG, 2005 Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118 3523 3530
206. Wu B, Liu Q, Duan C, Li Y, Yu S, Chan P, Ueda K, Yang H, 2011 Phosphorylation of alpha-synuclein upregulates tyrosine hydroxylase activity in MN9D cells. Acta Histochem 113 32 35
207. Lou H, Montoya SE, Alerte TN, Wang J, Wu J, Peng X, Hong CS, Friedrich EE, Mader SA, Pedersen CJ, Marcus BS, McCormack AL, Di Monte DA, Daubner SC, Perez RG, 2010 Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 285 17648 17661
208. Chadchankar H, Ihalainen J, Tanila H, Yavich L, 2011 Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein. Brain Res 1382 37 44
209. Al-Wandi A, Ninkina N, Millership S, Williamson SJ, Jones PA, Buchman VL, 2010 Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 31 796 804
210. Garcia-Reitboeck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK, Buchman VL, Spillantini MG, 2013 Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Exp Neurol 248 541 545
211. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL, 2004 Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 89 1126 1136
212. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC, 2004 Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proc Natl Acad Sci U S A 101 14966 14971
213. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ, Wade-Martins R, 2008 Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27 947 957
214. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B, 1999 alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19 5782 5791
215. Kim TD, Paik SR, Yang CH, Kim J, 2000 Structural changes in alpha-synuclein affect its chaperone-like activity. Protein Sci 9 2489 2496
216. Ahn M, Kim S, Kang M, Ryu Y, Kim TD, 2006 Chaperone-like activities of alpha-synuclein: Alha-synuclein assists enzyme activities of esterases. Biochem Biophys Res Commun 346 1142 1149
217. Rekas A, Adda CG, Andrew Aquilina J, Barnham KJ, Sunde M, Galatis D, Williamson NA, Masters CL, Anders RF, Robinson CV, Cappai R, Carver JA, 2004 Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: Effects on amyloid fibril formation and chaerone activity. J Mol Biol 340 1167 1183
218. Kim TD, Paik SR, Yang CH, 2002 Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41 13782 13790
219. Kim TD, Choi E, Rhim H, Paik SR, Yang CH, 2004 Alpha-synuclein has structural and functional similarities to small heat shock proteins. Biochem Biophys Res Commun 324 1352 1359
220. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM, 2000 Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97 279 284
221. da Costa CA, Ancolio K, Checler F, 2000 Wild-type but not Parkinson's disease-related ala-53 ->Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 275 24065 24069
222. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC, 2005 Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 383 396
223. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, Chandra SS, 2010 alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A 107 19573 19578
224. Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL, 2011 Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31 7264 7274
225. George JM, Jin H, Woods WS, Clayton DF, 1995 Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 361 372
226. Pelkonen A, Yavich L, 2011 Neuromuscular pathology in mice lacking alpha-synuclein. Neurosci Lett 487 350 353
227. Kokhan VS, Van'kin GI, Ninkina NN, Shelkovnikova TA, Bachurin SO, 2011 Impaired spatial and working memory in ageing mice with targeted inactivation of alpha-synuclein gene. Dokl Biol Sci 441 354 356
228. Kokhan VS, Afanasyeva MA, Van'kin GI, 2012 alpha-Synuclein knockout mice have cognitive impairments. Behav Brain Res 231 226 230
229. Watson JB, Hatami A, David H, Masliah E, Roberts K, Evans CE, Levine MS, 2009 Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 159 501 513
230. Steidl JV, Gomez-Isla T, Mariash A, Ashe KH, Boland LM, 2003 Altered short-term hippocampal synaptic plasticity in mutant alpha-synuclein transgenic mice. Neuroreport 14 219 223
231. Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins RD, Arancio O, 2004 alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 23 4506 4516
232. Gureviciene I, Gurevicius K, Tanila H, 2007 Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis 28 83 89
233. Gureviciene I, Gurevicius K, Tanila H, 2009 Aging and alpha-synuclein affect synaptic plasticity in the dentate gyrus. J Neural Transm 116 13 22
234. Martin ED, Gonzalez-Garcia C, Milan M, Farinas I, Cena V, 2004 Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. Eur J Neurosci 20 3085 3091
235. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH, 2010 Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65 66 79
236. Wu N, Joshi PR, Cepeda C, Masliah E, Levine MS, 2010 Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res 88 1764 1776
237. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D, 2006 Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26 11915 11922
238. Busch DJ, Oliphint PA, Walsh RB, Banks SM, Woods WS, George JM, Morgan JR, 2014 Acute increase of alpha-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. Mol Biol Cell 25 3926 3941
239. Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS, 2014 Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 34 9364 9376
240. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R, 2009 Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10 218 234
241. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH, 2005 Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25 10913 10921
242. Fortin DL, Nemani VM, Nakamura K, Edwards RH, 2010 The behavior of alpha-synuclein in neurons. Mov Disord 25 Suppl 1 S21 S26
243. Tao-Cheng JH, 2006 Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 141 1217 1224
244. Scott D, Roy S, 2012 alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32 10129 10135
245. Lai Y, Kim S, Varkey J, Lou X, Song JK, Diao J, Langen R, Shin YK, 2014 Nonaggregated alpha-synuclein influences SNARE-dependent vesicle docking via membrane binding. Biochemistry 53 3889 3896
246. Diao J, Burré J, Vivona S, Cipriano DJ, Sharma M, Kyoung M, Sudhof TC, Brunger AT, 2013 Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2 e00592
247. Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, Burd CG, Lee VM, 2008 Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell 19 1093 1103
248. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S, 2008 The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105 145 150
249. Lee SJ, Jeon H, Kandror KV, 2008 Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol Exp (Wars) 68 509 515
250. Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, Goedert M, Spillantini MG, 2010 SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133 2032 2044
251. Lee HJ, Kang SJ, Lee K, Im H, 2011 Human alpha-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. Biochem Biophys Res Commun 412 526 531
252. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ, 2002 Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 277 48984 48992
253. Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, Lee NK, Shin YK, 2013 Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A 110 4087 4092
254. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG, 2003 Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 486 489
255. Volles MJ, Lansbury PT Jr, 2003 Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42 7871 7878
256. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ, 2009 Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106 13010 13015
257. Rey NL, Petit GH, Bousset L, Melki R, Brundin P, 2013 Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 126 555 573
258. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM, 2012 Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 949 953
259. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM, 2011 Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 57 71